Skip to main content
Signal8
Launch Terminal

Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Zentalis Pharmaceuticals, Inc. logo

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTLHealthcare
-1.51%$1.96
AH$1.96-0.02%vs close
Mkt Cap$192.34M
Float96.76M
O/S98.13M
Vol
$ Vol
RVOL
Inst Own48.0%
SI6.2%
Earnings
Dilution
Zentalis Pharmaceuticals, Inc. logoNASDAQ:ZNTL$1.96-1.51%
FormDescription
13G/A
Beneficial Ownership Report (Amended)
4
Statement of Changes in Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
2
4
Statement of Changes in Beneficial Ownership
8-K
8.01,9.01
4
424B5
Prospectus Supplement
5
13G/A
Beneficial Ownership Report (Amended)
424B5
Prospectus Supplement
5
10-Q
Quarterly Report
5
8-K
2.02,7.01
5
13G
Beneficial Ownership Report
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
5.07
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
DEFA14A
Additional Proxy Materials
8-K
5.02
8-K
7.01,8.01
3
10-Q
Quarterly Report
8-K
2.02,7.01
8-K
7.01,8.01
3

1-25 of 546

…